Clinical Trial Update: Protective Effect of Sivelestat Against Negative Pulmonary Function and Organ Dysfunction After Cardiovascular Surgery (PANDA VI) [NA]

View source ↗

Summary

This document reports that the PANDA VI trial evaluating sivelestat for protection against negative pulmonary function and organ dysfunction after cardiovascula…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Aortic Dissection
• Cardiovascular Disease
• Systemic Inflammatory Response Syndrome

Drugs mentioned

• Sivelestat (sivelestat)

Snippet

Sponsor: Nanjing Medical University | Conditions: Aortic Dissection, Systemic Inflammatory Response Syndrome | NA | Status: RECRUITING